Loss of 13q is associated with genes involved in cell cycle and proliferation in dedifferentiated hepatocellular carcinoma

Modern Pathology

Volumn 21, Issue 12, 2008, Pages 1479-1489

  Skawran, Britta ^a   Steinemann, Doris ^a   Becker, Thomas ^a   Buurman, Reena ^a   Flik, Jakobus ^a   Wiese, Birgitt ^a   Flemming, Peer ^a   Kreipe, Hans ^a   Schlegelberger, Brigitte ^a   Wilkens, Ludwig ^a,b  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b UNIVERSITY OF BERN   (Switzerland)

Author keywords

Cell cycle; Chromosomal instability; Gene expression; Hepatocellular carcinoma; microRNA; Proliferation

Indexed keywords

CCAAT ENHANCER BINDING PROTEIN ALPHA; METALLOTHIONEIN; MICRORNA; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B;

ADULT; AGED; ARTICLE; BIC GENE; CELL CYCLE; CELL CYCLE REGULATION; CELL PROLIFERATION; CHROMOSOME 13Q; CHROMOSOME LOSS; CLINICAL ARTICLE; COMPARATIVE GENOMIC HYBRIDIZATION; CPNE1 GENE; DOWN REGULATION; FEMALE; GENE; GENE CLUSTER; GENE EXPRESSION; HUMAN; HUMAN TISSUE; LIVER CELL CARCINOMA; MALE; MICROARRAY ANALYSIS; PRIORITY JOURNAL; RBPMS GENE; RFC4 GENE; RPSA GENE; SCHOOL CHILD; TOP2A GENE; UPREGULATION;

ADULT; AGED; CARCINOMA, HEPATOCELLULAR; CELL CYCLE; CELL DIFFERENTIATION; CELL PROLIFERATION; CHILD; CHROMOSOMES, HUMAN, PAIR 13; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; MICRORNAS; MIDDLE AGED; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 56649097358     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2008.147     Document Type: Article

References (44)

1. El-Serag HB. Hepatocellular carcinoma: an epidemiologic view. J Clin Gastroenterol 2002;35(5 Suppl 2):72-78.
2. Thorgeirsson SS, Grisham JW. Molecular pathogenesis of human hepatocellular carcinoma. Nat Genet 2002;31:339-346.
3. Wiemann SU, Satyanarayana A, Buer J, et al. Contrasting effects of telomere shortening on organ homeostasis, tumor suppression, and survival during chronic liver damage. Oncogene 2005;24:1501-1509.
4. Plentz RR, Caselitz M, Bleck JS, et al. Hepatocellular telomere shortening correlates with chromosomal instability and the development of human hepatoma. Hepatology 2004;40:80-86.
5. Mitelman F. Catalog of Chromosome Aberrations in Cancer. 5th edn. Wiley-Liss: New York, 1994.
6. Rajagopalan H, Lengauer C. Aneuploidy and cancer. Nature 2004;432:338-341.
7. Marchio A, Meddeb M, Pineau P, et al. Recurrent chromosomal abnormalities in hepatocellular carcinoma detected by comparative genomic hybridization. Genes Chromosomes Cancer 1997;18:59-65.
8. Wong N, Lai P, Lee SW, et al. Assessment of genetic changes in hepatocellular carcinoma by comparative genomic hybridization analysis: relationship to disease stage, tumor size, and cirrhosis. Am J Pathol 1999;154:37-43.
9. Kusano N, Shiraishi K, Kubo K, et al. Genetic aberrations detected by comparative genomic hybridization in hepatocellular carcinomas: their relationship to clinicopathological features. Hepatology 1999;29:1858-1862.
10. Wilkens L, Bredt M, Flemming P, et al. Diagnostic impact of fluorescence in situ hybridization in the differentiation of hepatocellular adenoma and well-differentiated hepatocellular carcinoma. J Mol Diagn 2001;3:68-73.
11. Moinzadeh P, Breuhahn K, Stutzer H, et al. Chromosome alterations in human hepatocellular carcinomas correlate with aetiology and histological grade - results of an explorative CGH meta-analysis. Br J Cancer 2005;92:935-941.
12. Laurent-Puig P, Legoix P, Bluteau O, et al. Genetic alterations associated with hepatocellular carcinomas define distinct pathways of hepatocarcinogenesis. Gastroenterology 2001;120:1763-1773.
13. Hashimoto K, Mori N, Tamesa T, et al. Analysis of DNA copy number aberrations in hepatitis C virus-associated hepatocellular carcinomas by conventional CGH and array CGH. Mod Pathol 2004;17:617-622.
14. Sy SM, Wong N, Lai PB, et al. Regional over-representations on chromosomes 1q, 3q and 7q in the progression of hepatitis B virus-related hepatocellular carcinoma. Mod Pathol 2005;6:86-92.
15. Guan XY, Fang Y, Sham JS, et al. Recurrent chromosome alterations in hepatocellular carcinoma detected by comparative genomic hybridization. Genes Chromosomes Cancer 2000;29:110-116.
16. Steinemann D, Skawran B, Becker T, et al. Assessment of differentiation and progression of hepatic tumors using array- based comparative genomic hybridization. Clin Gastroenterol Hepatol 2006;4:1283-1291.
17. Wilkens L, Flemming P, Gebel M, et al. Induction of aneuploidy by increasing chromosomal instability during dedifferentiation of hepatocellular carcinoma. Proc Natl Acad Sci USA 2004;101:1309-1314.
18. Nzeako UC, Goodman ZD, Ishak KG. Comparison of tumor pathology with duration of survival of North American patients with hepatocellular carcinoma. Cancer 1995;76:579-588.
19. Lauwers GY, Terris B, Balis UJ, et al. Prognostic histologic indicators of curatively resected hepatocellular carcinomas: a multi-institutional analysis of 425 patients with definition of a histologic prognostic index. Am J Surg Pathol 2002;26:25-34.
20. Kenmochi K, Sugihara S, Kojiro M. Relationship of histologic grade of hepatocellular carcinoma (HCC) to tumor size, and demonstration of tumor cells of multiple different grades in single small HCC. Liver 1987;7:18-26.
21. Sugihara S, Nakashima O, Kojiro M, et al. The morphologic transition in hepatocellular carcinoma. A comparison of the individual histologic features disclosed by ultrasound-guided fine-needle biopsy with those of autopsy. Cancer 1992;70:1488-1492.
22. Skawran B, Steinemann D, Weigmann A, et al. Gene expression profiling in hepatocelluar carcinoma: coordinated up-regulation of genes localised in amplified chromosome regions. Mod Pathol 2008;21:505-516.
23. Ishak KG, Anthony PP, Sobin LH. Histological typing of tumours of the liver. World Health Organization International Histological Classification of Tumours. 2nd edn. Springer-Verlag: Berlin, 1994.
24. Shaffer LG, Tommerup N, eds. ISCN 2005: An International System for Human Cytogenetic Nomenclature. S. Karger: Basel, 2005.
25. Tusher VG, Tibshirani R, Chu G. Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci USA 2001;98:5116-5121.
26. Neo SY, Leow CK, Vega VB, et al. Identification of discriminators of hepatoma by gene expression profiling using a minimal dataset approach. Hepatology 2004;39:944-953.
27. Wu CG, Salvay DM, Forgues M, et al. Distinctive gene expression profiles associated with Hepatitis B virus x protein. Oncogene 2001;20:3674-3682.
28. Smith MW, Yue ZN, Geiss GK, et al. Identification of novel tumor markers in hepatitis C virus-associated hepatocellular carcinoma. Cancer Res 2003;63:859-864.
29. Shirota Y, Kaneko S, Honda M, et al. Identification of differentially expressed genes in hepatocellular carcinoma with cDNA microarrays. Hepatology 2001;33:832-840.
30. Okabe H, Satoh S, Kato T, et al. Genome-wide analysis of gene expression in human hepatocellular carcinomas using cDNA microarray: identification of genes involved in viral carcinogenesis and tumor progression. Cancer Res 2001;61:2129-2137.
31. Iizuka N, Oka M, Yamada-Okabe H, et al. Molecular signature in three types of hepatocellular carcinoma with different viral origin by oligonucleotide microarray. Int J Oncol 2004;24:565-574.
32. Clurman BE, Hayward WS. Multiple proto-oncogene activations in avian leukosis virus-induced lymphomas: evidence for stage-specific events. Mol Cell Biol 1989;9:2657-2664.
33. Eis PS, Tam W, Sun L, et al. Accumulation of miR-155 and BIC RNA in human B cell lymphomas. Proc Natl Acad Sci USA 2005;102:3627-3632.
34. Tam W, Hughes SH, Hayward WS, et al. Avian bic, a gene isolated from a common retroviral site in avian leukosis virus-induced lymphomas that encodes a noncoding RNA, cooperates with c-myc in lymphomagenesis and erythroleukemogenesis. J Virol 2002;76:4275-4286.
35. Nakopoulou L, Lazarisa AC, Kavantzasa N, et al. DNA topoisomerase II-alpha immunoreactivity as a marker of tumor aggressiveness in invasive breast cancer. Pathobiology 2000;68:137-143.
36. Theocharis SE, Margeli AP, Klijanienko JT, et al. Metallothionein expression in human neoplasia. Histopathology 2004;45:103-118.
37. Deng DX, Chakrabarti S, Waalkes MP, et al. Metallothionein and apoptosis in primary human hepatocellular carcinoma and metastatic adenocarcinoma. Histopathology 1998;32:340-347.
38. Endo T, Yoshikawa M, Ebara M, et al. Immunohistochemical metallothionein expression in hepatocellular carcinoma: relation to tumor progression and chemoresistance to platinum agents. J Gastroenterol 2004;39:1196-1201.
39. Ebara M, Fukuda H, Hatano R, et al. Relationship between copper, zinc and metallothionein in hepatocellular carcinoma and its surrounding liver parenchyma. J Hepatol 2000;33:415-422.
40. Quaife CJ, Cherne RL, Newcomb TG, et al. Metallothionein overexpression suppresses hepatic hyperplasia induced by hepatitis B surface antigen. Toxicol Appl Pharmacol 1999;155:107-116.
41. Suzuki JS, Nishimura N, Zhang B, et al. Metallothionein deficiency enhances skin carcinogenesis induced by 7,12-dimethylbenz[a]anthracene and 12-O-tetradecanoylphorbol-13-acetate in metallothionein-null mice. Carcinogenesis 2003;24:1123-1132.
42. Waalkes MP, Liu J, Kasprzak KS, et al. Hypersusceptibility to cisplatin carcinogenicity in metallothionein-I/II double knockout mice: production of hepatocellular carcinoma at clinically relevant doses. Int J Cancer 2006;119:28-32.
43. Datta J, Majumder S, Kutay H, et al. Metallothionein expression is suppressed in primary human hepatocellular carcinomas and is mediated through inactivation of CCAAT/enhancer binding protein alpha by phosphatidylinositol 3-kinase signaling cascade. Cancer Res 2007;67:2736-2746.
44. Pang RW, Poon RT. From molecular biology to targeted therapies for hepatocellular carcinoma: the future is now. Oncology 2007;72(Suppl 1):30-44.